RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity

Nat Cancer. 2021 Oct;2(10):1018-1038. doi: 10.1038/s43018-021-00263-z. Epub 2021 Oct 22.

Abstract

Expanding the utility of immune-based cancer treatments is a clinical challenge due to tumor-intrinsic factors that suppress the immune response. Here we report the identification of tumoral ring finger protein 2 (RNF2), the core subunit of polycomb repressor complex 1, as a negative regulator of antitumor immunity in various human cancers, including breast cancer. In syngeneic murine models of triple-negative breast cancer, we found that deleting genes encoding the polycomb repressor complex 1 subunits Rnf2, BMI1 proto-oncogene, polycomb ring finger (Bmi1), or the downstream effector of Rnf2, remodeling and spacing factor 1 (Rsf1), was sufficient by itself to induce durable tumor rejection and establish immune memory by enhancing infiltration and activation of natural killer and CD4+ T cells, but not CD8+ T cells, into the tumor and enabled their cooperativity. These findings uncover an epigenetic reprogramming of the tumor-immune microenvironment, which fosters durable antitumor immunity and memory.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Humans
  • Mice
  • Neoplasms* / genetics
  • Nuclear Proteins
  • Polycomb Repressive Complex 1 / genetics
  • Polycomb Repressive Complex 1 / metabolism*
  • Polycomb-Group Proteins
  • Trans-Activators
  • Tumor Microenvironment* / genetics
  • Ubiquitin-Protein Ligases / metabolism*

Substances

  • Nuclear Proteins
  • Polycomb-Group Proteins
  • RSF1 protein, human
  • Trans-Activators
  • Polycomb Repressive Complex 1
  • RNF2 protein, human
  • Rnf2 protein, mouse
  • Ubiquitin-Protein Ligases